U phosphoramidite 10. a) Br2, pyridine in H2O, 0°C -rt, 14h, 45%; b) p-tolunesulfonic acid in dimethoxypropane, 50°C, 1h, 97%; c) ethyl-2-iodo acetate in EtOH (55%)/NaOH (1M) (5/1), rt, 16h, 65%; d) concentrated aqueous HCl in MeOH, 50°C, 1h, 92%; e) ditert.-butylsilyl bistriflate, imidazole, then tert.-butyldimethylsilyl chloride in anhydrous DMF, 0 -50°C, 3h, 68%; f) NaOH in pyridine/MeOH (1/1), rt, 10min, 87%; g) 4-nitrophenylethanol (NPE), DMAP, EDC in anhydrous THF, rt, 2h, quant.; h) HF, pyridine in anhydrous CH2Cl2, 0°C, 1h, then DMT-Cl in anhydrous pyridine, rt, 16h, 26%; i) BTT, TIPCEP in anhydrous acetonitrile, rt, 4h, 79%.
2-Cyano acetic acid (2)
2-Bromo acetic acid (1, 14.00 g, 100.8 mmol, 1.00 eq) was dissolved in 40 mL H2O and stirred at room temperature. Thus, a solution of NaHCO3 (2.71 g, 32.24 mmol, 0.32 eq) in 20 mL H2O was added followed by a solution of KCN (6.36 g, 97. 73 mmol, 0.97 eq) in 20 mL H2O. The mixture was stirred at 80°C for 16 hours prior to being quenched with conc. HCl until pH 1. After evaporation of the solvent, 2-cyano acetic acid was extracted with ether. The salt was filtered off and the filtrate was concentrated and dried under high vacuum to yield 8.50 g 2-cyano acetic acid as a white solid (2, 99.9 mmol, quant.).
13
C-NMR (300 MHz, DMSO-d6, 25°C): δ 165.81 (C1(O)OH); 115.66 (C3N); 24.74 (C2H2) ppm.
15 N2-N-Carbamoyl-2-cyanoacetamide (3)
A mixture of 2-cyano acetic acid (2, 8.80 g, 103 mmol, 1.00 eq) and 15 N2-urea (6.80 g, 110 mmol, 1.06 eq) was dissolved in acetic anhydride and stirred at 90°C for 30 minutes until white precipitation. Thus, the reaction mixture was cooled to 0°C, filtered, the white solid was washed with 500 mL ether and dried under high vacuum to yield 9.49 g 15 N2-N-carbamoyl-2-cyanoacetamide (3, 73.5 mmol, 71%), which was used without further purification and characterization.
1,3-

15
N2-Uracil (4)
Palladium on BaSO4 (4.80 g, 5% Pd-basis) was dissolved in a mixture of 60 mL acetic acid and H2O (1/1) and put under hydrogen atmosphere under vigorous stirring. Thus, 15 N2-N-carbamoyl-2-cyanoacetamide (3, 9.49 g, 73.6 mmol, 1.00 eq) was dissolved in a mixture of 240 mL acetic acid and H2O (1/1) at 80°C and was added to the stirring Palladium-acetic acid-water suspension. The reaction mixture was stirred under hydrogen atmosphere at room temperature for 20 hours, followed by 1.5 hours at 70°C. After the suspension was filtered over celite and washed with hot water, the mother lye was concentrated at 45°C until precipitation started. The product crystallized at 0°C, was filtrated, washed with cold water and dried under high vacuum to give 3.33 g 1,3-15 N2-uracil (4, 28.9 mmol, 40%) as a white powder. -uracil (4, 3.30 g, 28. 9 mmol, 1.00 eq) and 1-O-Acetyl-2,3,5-tri-O-benzoyl-β-Dribofuranose (ATBR, 14.01 g, 28.9 mmol, 1.00 eq) was dissolved in 40 mL anhydr. acetonitrile and was stirred at room temperature under Argon atmosphere. Bis(trimethylsilyl)acetamide (BSA, 21.2 mL, 86.8 mmol, 3.00 eq) was added and the solution was refluxed at 60°C for 30 minutes. Thus, trimethylsilyltriflate (18.3 mL, 101 mmol, 3.50 eq) was added slowly and the reaction mixture was stirred at 60°C for another 30 minutes, before being allowed to cool to room temperature. After evaporation of the solvent, the residue was dissolved in CH2Cl2, washed twice with sat. NaHCO3, dried over Na2SO4, filtered and concentrated to yield 16.20 g 1,3- N2-Uridine (6, 7.11 g, 28.9 mmol, 1.00 eq) was dissolved in H2O and bromine (14.1 mL, 274 mmol, 9.50 eq) was added slowly under stirring. Excess of bromine was extracted with ethyl acetate. Thus, pyridine (20.9 mL, 260 mmol, 9.00 eq) was added dropwise at 0°C and the solution was stirred at room temperature for 14 hours. After evaporation of the solvent and co-evaporation with toluene, the crude was dissolved in H2O and washed with ethyl acetate. The org. phase was extracted with H2O and the combined aq. phases were concentrated and dried under high vacuum. Recrystallization from ethanol yielded 3.40 g 1,3-15 N2-5-hydroxy uridine (7, 28.9 mmol, 45%). N2-5-hydroxy uridine (7, 1.90 g, 7.25 mmol, 1.00 eq) and para-toluene sulfonic acid (125 mg, 725 µmol, 0.10 eq) was suspended in dimethoxypropane and stirred at room temperature for 16 hours. Thus, the solution was neutralized with 100 µl TEA, concentrated, co-evaporated with CH2Cl2 and dried under high vacuum to give 2.62 g as a mixture of 1,3- N2-5-Hydroxy-2',3'-O-isopropylidene-5'-O-(2''-methoxypropyl) uridine (8, 2.62 g, 7.00 mmol, 1.00 eq) was dissolved in a mixture of EtOH (55%) and NaOH (1M) (5/1) and stirred at room temperature. Thus, ethyl-2-iodo acetate (3.31 mL, 28.0 mmol, 4.00 eq) was added in portions over 2 hours and the solution was stirred for additional 30 minutes. After neutralization with acetic acid, the solvent was evaporated and the dry residue was dissolved in CHCl3. The org. phase was washed with cold H2O, dried over Na2SO4, concentrated and dried under high vacuum. N2-5-Ethylcarboxymethoxy-2',3'-O-isopropylidene uridine (9, 1.76 g, 4.53 mmol, 1.00 eq) was dissolved in methanol and conc. HCl was added until pH = 1. The solution was stirred at 50°C for 1 hour. Thus, the solvent was evaporated, co-evaporated with methanol and dried under high vacuum to yield 1.40 g 1,3-15 N2-5-methylcarboxymethoxy uridine (10, 4.53 mmol, 92%), which was not further purified or characterized. 19 mmol, 1.00 eq) was dissolved in anhydr. DMF and stirred at 0°C under Argon. Thus, di-t-butylsilyl bis(trifluoromethanesulfonate) (3.55 mL, 10.9 mmol, 2.60 eq) was added and the solution was stirred at 0°C for 30 minutes. Imidazole (1.43 g, 20.9 mmol, 5.00 eq) was added and the reaction mixture was allowed to warm to room temperature and stir for 20 minutes. After the addition of t-butyl dimethylsilyl chloride (1.70 g, 11.3 mmol, 2.70 eq) the solution was stirred at 50°C for 3 hours. The solvent was evaporated and the residue was dissolved in CH2Cl2. The org. phase was washed with half-sat. NaCl, dried over Na2SO4, concentrated and dried under high vacuum. The crude was purified via column chromatography (SiO2, ethyl acetate/hexane 1/9 -2/8 -3/7 -4/6) to give 1.67 g 1,3- 
1,3-
15
N2-5-Carboxymethoxy-2'-O-(t-butyldimethylsilyl)-3',5'-O-(di-t-butylsilyl) uridine (12)
84 mmol, 1.00 eq) was dissolved in a mixture of pyridine and methanol (1/1) and was stirred at room temperature. Thus, NaOH in methanol (8.51 mL, 17.0 mmol, 2 M, 6.00 eq) was added and the solution was stirred for 10 minutes. After evaporation of the solvent mixture, the residue was suspended in CH2Cl2, neutralized with conc. HCl and washed with 0.5 M HCl. The org. phase was dried over Na2SO4 and concentrated to yield 1.41 g 1,3-15 N2-5-carboxymethoxy-2'-O-(t-butyldimethylsilyl)-3',5'-O-(di-tbutylsilyl) uridine (12, 2.45 mmol, 87%) as a white foam. The product was used for the next step without further purification or characterization.
1,3-
15
N2-5-(4-nitrophenylethylcarboxymethoxy)-2'-O-(t-butyldimethylsilyl)-3',5'-O-(di-tbutylsilyl) uridine (13)
A mixture of 1,3-15 N2-5-carboxymethoxy-2'-O-(t-butyldimethylsilyl)-3',5'-O-(di-t-butylsilyl) uridine (12, 1.41 g, 2.45 mmol, 1.00 eq), nitrophenyl ethanol (902 mg, 5.40 mmol, 2.20 eq) and N-dimethyl amino pyridine (30.0 mg, 245 µmol, 0.10 eq) was dissolved in anhydr. THF and stirred at room temperature under Argon. Thus, N-Ethyl-N′-(3-dimethyl aminopropyl) carbodiimide (EDC, 1.13 ml, 6.38 mmol, 2.60 eq) was added and the solution was stirred at room temperature for 2 hours. After dilution with CH2Cl2, the org. phase was washed with half-sat. NaHCO3, dried over Na2SO4 and concentrated to yield 1.77 g of 1,3- 
N2-5-(4-nitrophenylethylcarboxymethoxy)-2'-O-(t-butyldimethylsilyl) uridine (14)
1,3-
44 mmol, 1.00 eq) was dissolved in anhydr. CH2Cl2 and stirred at 0°C under Argon. Thus, hydrogen fluoride in pyridine (240 µL, 9.41 mmol, 3.85 eq) was diluted with excess pyridine (1.52 mL, 18.8 mmol, 7.70 eq) and was added to the cooled solution and stirred for 1 hour. After complete conversion, the org. phase was washed with sat. NaHCO3 and 5% citric acid, dried over Na2SO4 and concentrated. 1.42 g 1,3- 46 mmol, 1.00 eq) was co-evaporated with anhydr. pyridine and dissolved in anhydr. pyridine. 4,4'-Dimethoxytrityl chloride (1.66 g, 4.92 mmol, 2.00 eq) was added in three portions and the solution was stirred at room temperature for 16 hours under Argon. Thus, the solvent was evaporated, the residue was dissolved in CH2Cl2 and washed with sat. NaHCO3 and 5% citric acid. The org. fractions were combined, dried over Na2SO4 and concentrated. (CH3)3) ; -5.23 (2x CH3) ppm.
1,3-
15
N2-5-(4-nitrophenylethylcarboxymethoxy)-2'-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl) uridine 3'-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (16)
1,3-15 N2-5-(4-nitrophenylethylcarboxymethoxy)-2'-O-(t-butyldimethylsilyl)-5'-O-(4,4'-dimethoxytrityl) uridine (15, 570 mg, 645 µmol, 1.00 eq) was dissolved in anhydr. acetonitrile and stirred at room temperature under Argon. Thus, 5-(benzylthio)-1H-tetrazole (136 mg, 709 µmol, 1.10 eq) was added and the solution was stirred for 1 hour. After addition of N,N-(tetraisopropyl)-cyanoethyl phosphane (307 µl, 967 µmol, 1.50 eq) the solution was stirred at room temperature for another 4 hours. The reaction mixture was diluted with CH2Cl2, washed with half-sat. NaHCO3, dried over Na2SO4 and concentrated. The crude was purified via column chromatography (SiO2, ethyl acetate/hexane 8/2 -1/0 + TEA 1%) to yield 550 mg 1,3-15 N2-5-Methylcarboxymethoxy uridine (10, 200 mg, 602 µmol, 1.00 eq) was suspended in H2O and stirred at room temperature. Thus, aq. NaOH (622 µl, 622 µmol, 1M, 1.10 eq) was added and the solution was stirred for 1 hour. After completion, the reaction mixture was neutralized with conc. HCl, concentrated, desalted over size exclusion column and dried under HV to give 191 mg pure 1,3- 1.5 ml freshly prepared 1 M tetrabutylammonium fluoride (TBAF) solution in anhydrous THF were added to the flask. After the RNA has fully dissolved, the flask was sealed with a glass stopper and incubated at 37°C for 20-24 hours. Then, the deprotection solution was quenched with 1.5 ml 1 M triethyl ammonium acetate (TEAA). The THF was evaporated and the concentrated solution was applied to a HiPrep 26/10 desalting column (GE Healthcare) using a ÄKTA start system (GE Healthcare). The crude RNA was eluted using HPLC grade water and the RNA containing fractions (UV detection at 254 nm)
N2-5-(4-nitrophenylcarboxymethoxy)-2'-O-(t-butyldimethylsilyl) -5'-O-(4,4'-dimethoxytrityl) uridine 3'-O-(2-cyanoethyl-N,N-diisopropylphosphoramidite) (
were collected in a 50 mL round bottom flask. After evaporation, the crude RNA was dissolved in 1 mL HPLC grade water and transferred to a 1.5 mL reaction tube. The crude RNA was stored at -20°C. The quality of the crude RNAs was checked via anion exchange chromatography on an analytical Dionex DNAPac PA-100 column (4x250 mm; Eluent A: 25 mM Tris.HCl, 6 M urea, pH 8.0; Eluent B: 25 mM Tris.HCl, 500 mM sodium perchlorate, 6 M urea, pH 8.0) and at elevated temperature (80 °C).
Purification of the RNA sequences was achieved in a single run by applying the crude RNA on a preparative Dionex DNAPac PA-100 column (22x250 mm, eluents as before). The fractions containing the desired RNA were pooled and loaded on a C18 SepPak catridge (Waters) to remove HPLC buffer salts. The RNA sodium salt form was then eluted from the C18 column with water/acetonitrile (1/1, v/v), concentrated and transferred to a 1.5 ml reaction tube for concentration evaluation and mass spectrometric analysis. Sample concentrations were determined by measuring UV absorption at 260 nm on a NanoPhotometer (Implen). 
Measurement of UV melting curves and extraction of thermodynamic data
Appropriate amounts of unmodified and cmo 5 U-modified RNAs were lyophilized and then dissolved in 800 µL melting curve buffer (10 mM sodium phosphate, pH 7.0, 150 mM NaCl) to give RNA concentrations of 2 and 5 µM. Absorbance versus temperature profiles were recorded at 250 nm and 260 nm on a Cary-100 spectrophotometer equipped with a multiple cell holder and a Peltier temperature-control device. Data were collected for five heating-cooling cycles at a rate of 0.7 °C/minute. Melting transitions were essentially the same with respect to the two different wavelengths and heating-cooling cycles. Melting point temperatures are reported as mean value of the five measurements.
The thermodynamic parameters of the monomolecular melting process were obtained by plotting the association degree a versus temperature and fitting the experimental data in KaleidaGraph (Synergy Software using the following equation:
with a association degree and R ideal gas constant to give the enthalpy DH 0 and the entropy DS 0 of the melting transition.
Supporting Figure 3 . UV melting curve data of all four RNA constructs for the extraction of the thermodynamic data.
NMR sample preparation
RNA samples were lyophilized as sodium salts and dissolved in the respective buffer: 15 mM sodium phosphate, 25 mM NaCl, 0.1 mM EDTA, pH 6.9 or 8.0, at 5 -25 °C.
Determination of imino proton water exchange rates by CLEANEX-PM experiment
The CLEANEX-PM NMR experiments were carried out on unlabeled RNAs in the standard buffer (15 mM sodium phosphate, 25 mM NaCl, 0.1 mM EDTA, pH 6.9) at 25 °C. The same buffer stock solution was used for all samples to rule out changes in imino proton -bulk water exchange rates due to differences in the buffer composition. The CLEANEX-PM pulse sequence is available from the Bruker standard experiment collection (zgcxesgp) with an excitation sculpting water suppression element. A standard excitation sculpting water suppression experiment (zgesgp) was used as the reference experiment. For the determination of the water T1 relaxation times under the experimental conditions a saturation recovery experiment was used and the longitudinal water relaxation time ranged between 3.00 and 3.33 s (R1,water = 0.333 -0.309 s -1
). The following experimental parameters were used: spectral width 24 ppm, o1p: 4.7 ppm, number of scans 1024, dummy scans 32, interscan delay 1.5 s. Shaped pulse parameters were set via the getprosol command and the hard 90° 1H pulse. The mixing times were set to 5, 20, 30, 50, 50, 75, 100, 150, 200, 250, 300, 300, 350, 400 , 500 and 500 milliseconds. for the U-A, U•G and cmo 5 U-A construct. For the cmo 5 U•G the CLEANEX mixing times were set to 10, 25, 50, 75, 75, 100, 125, 150, 150, 175, 200, 250 , 300 and 300 milliseconds. The NMR spectra were processed in TOPSPIN 3.5 pl7 using a line broadening factor of 10 Hz (lb value set to 10). The absolute peak intensities of the CLEANEX-PM experiments and the reference experiments were determined and used to obtain the relative intensities.
The data was then exported to MATLAB and the build-up curves were fitted to the following equation:
with I/I0 relative peak intensity, k imino proton-bulk water exchange rate / s Exchange rates given in s -1
. Some exchange rates were not determinable either due to too slow exchange (e.g. G7), or the imino proton not being observable at 25 °C (e.g. G1), or resonance overlap (e.g. G4/6 in the hairpins with wobble mismatch). *cmo 5 U5 NH 3 imino proton exchange broadened beyond detection at 25 °C.
7
R1r r relaxation dispersion experiments
All RD data was collected on a 700 MHz Bruker Avance spectrometer equipped with cryogenic HCN probes using a 15 N R1ρ experiment as described previously. 1 Peaks from 1D experiments were fit to a Lorentzian peak shape, to extract peak intensities as a function of delay time, which were then fit to an exponential decay to get the R1ρ value for a given spin lock power offset combination. On-and offresonance R1ρ measurements were performed using spinlock powers ranging from 100 to 2,000 Hz, with the absolute offset frequencies (Ω 2π −1 Hz) ranging from 0 -3.5 × the applied spinlock power.
Errors in R1ρ were calculated using a Monte-Carlo approach as described previously. 
Supplementary
